Cost-Effectiveness of Pioglitazone in Type 2 Diabetes Patients With a History of Macrovascular Disease: A German Perspective

Cost Effectiveness and Resource Allocation - United Kingdom
doi 10.1186/1478-7547-7-9
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Springer Science and Business Media LLC


Related search